metricas
covid
Buscar en
Revista de Psiquiatría y Salud Mental (English Edition)
Toda la web
Inicio Revista de Psiquiatría y Salud Mental (English Edition) Towards a more clinically useful International World Health Organisation classif...
Información de la revista
Vol. 4. Núm. 3.
Páginas 113-116 (julio - septiembre 2011)
Vol. 4. Núm. 3.
Páginas 113-116 (julio - septiembre 2011)
Editorial
Acceso a texto completo
Towards a more clinically useful International World Health Organisation classification of Mental Disorders
Hacia una clasificación Internacional de los Trastornos Mentales de la OMS de mayor utilidad clínica
Visitas
3053
Geoffrey M. Reeda,
Autor para correspondencia
reedg@who.int

Corresponding author.
, José Luis Ayuso-Mateosb
a Departamento de Salud Mental y Abuso de Sustancias, Organización Mundial de la Salud, Geneva, Switzerland
b Departamento de Psiquiatría, Instituto de Investigación Sanitaria Hospital Universitario de la Princesa, Universidad Autónoma de Madrid, CIBERSAM, Madrid, Spain
Este artículo ha recibido
Información del artículo
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Texto completo

The descriptive approach based on diagnostic criteria that characterizes the ICD-101 and the DSM-IV2 has led to marked improvement around the world in the identification and treatment of mental disorders. However, even those who developed these systems recognize that their primary accomplishment has been the improved reliability of diagnosis.3 These benefits are most apparent in the research milieu, where explicit diagnostic criteria can be applied in the course of lengthy, complex, and costly standardized diagnostic interviews. There is no evidence of a parallel improvement in the reliability of diagnosis in daily clinical practice.4 The WHO is looking upon the current revision of the ICD as an opportunity to address several major issues with the present classifications of mental disorders, but it is placing greater importance on making them more clinically useful for healthcare professionals.

Four decades of research have failed to demonstrate that the current nosology for mental disorders is based on valid disease entities.5,6 The hope was that improved reliability, possibly through a symptom-based descriptive classification, would pave the way for corresponding gains in validity based on the results of clinical research and contributions from neuroscience and genetics. This has not happened either as quickly or as extensively as the scientific community had hoped.

Advances in research to date have yielded neither a clear structure nor a coherent set of principles around which a standardized system of diagnosis could be organized, nor have they led to the validation of individual diagnostic entities or clarification of their criteria. Given the evidence currently available, it would be prudent to point out that any improvement in the validity of classifications in the ICD-11 and DSM-5 is going to be modest and gradual, as would be expected with a reiterative process of successive approximations. In fact, Hyman—president of the International Consulting Group for revision of the chapter on mental and behaviour disorders in the WHO ICD-10 and also a member of the DSM-5 task force—has recently stated that validity of the classification system cannot be achieved simply by refining the criteria for existing disorders or adding new disorders.3

Even if conclusive proof of the validity of current diagnostic symptoms remains elusive, experts are increasingly concerned about the fact that there are serious issues with these symptoms in terms of their clinical usefulness.7–9 Several key issues stand out in the literature. First, a high proportion of diagnoses for mental disorders are recorded as “non-specific” (the term used in the ICD) or “not specified elsewhere” (the corresponding term in the DSM). This suggests that healthcare professionals find the present categories difficult to use or imprecise for describing their patients or that they do not find the nuances introduced by the diagnostic classification subtypes to be useful in clinical practice. Second, a high proportion of individuals with mental health problems meet the criteria for 2 or more disorders.10,11 In the majority of cases, these multiple diagnoses may be considered an artefact of the classification system in that they identify separately different aspects of a single underlying disease. This suggests that the existing systems are not properly capturing the nature of mental disorders. At the same time, other diagnostic categories are characterized by considerable heterogeneity, which may have a significant impact on treatment.

Third, very often the same psychotherapy or pharmacotherapy is effective for different mental disorders.12,13 This does not mean that the classification should be organized by response to treatment or that the existence of a specific treatment should be the acid test for inclusion of a category. It is clear, however that nowadays the classifications make numerous diagnostic distinctions that have no relevance to clinical practice.14–16 In the case of some disorders, it is possible for 2 individuals to have the same diagnosis but have none of the clinical features in common. For example, the DSM-IV diagnosis of behaviour disorder requires that only 3 of 15 possible criteria be present, and the diagnosis of substance dependence requires that only 3 of 7 symptoms be present. Finally, the diagnostic categories are poor predictors of treatment needs—especially in the case of individuals with the more severe types of mental disorder. In other words, the current systems of diagnosis are of no help when it comes to efficient use of a clinic or community's limited treatment resources.

One of the factors that limit the clinical usefulness of the current systems of diagnosis is their extraordinary complexity—each revision including more categories and subtypes focused on increasingly finer distinctions.17 What has spurred this increasing level of definition and complexity in the current systems of diagnosis for mental disorders is partly the very nature of the revision process—that it is incremental, within the framework of the existing system of diagnosis, and centred around the participation of researchers who have experience in specific diagnostic categories. As Watson and Clark18 point out that clinical usefulness is not taken into account by some psychopathology experts because they do not face the daily decision-making involved in treating individual patients. They have access to increasingly more sophisticated multivariate statistical techniques, which can fit complex hierarchical models with a wide range of predictor variables. They do not wish to give up the prospect of having the power—eventually, through the development of a more nuanced system—to explain the mechanisms and pathways of diseases and to address the comorbidity and heterogeneity issues. The nature of current approaches to diagnosis has been of benefit in certain aspects of research—in particular, trials of specific pharmacotherapies for an increasingly greater number of well-recognized mental disorders19—but it has been a limitation in other areas of research, such as the study of mechanisms common to different psychopathologies or studies on the efficacy of treatments across a cluster of disorders.3,20

One of the consequences of using classifications that introduce detailed specifications into the definition of a disorder is that, to diagnose a mental disorder, healthcare professionals typically have to consider 20–35 pieces of information.21 As different studies have discovered, however, there are very few resident and primary care physicians who are able to remember the key symptoms of mental disorders.22,23 Perhaps it could be expected that mental health professionals would have more detailed knowledge of the symptoms of mental disorders. However, as evidenced by the extremely low frequency, worldwide, of specialized treatment consultations for the majority of individuals with mental disorders,24 in most healthcare settings, it is much more important that the office time available be spent on choosing and explaining the most suitable therapeutic management strategy than on conducting detailed diagnostic interviews. In fact, there are studies showing that the level of detail in the definitions of and criteria for mental disorders may not actually be required. Two recent studies have shown that almost half of the existing criteria for major depression could be eliminated, with its explanatory power almost fully preserved.21,25 Similar results would probably be obtained for other disorders, but a systematic program of clinical and epidemiological research would be required for this.

In view of the issues described, the WHO has decided that improving clinical usefulness should be a guiding principle for the current revision of the ICD-10. Clinical usefulness is important to healthcare professionals because it impacts their daily practice.

Mental and neurological disorders represent a higher proportion of the disease and disability burden than any other category of non-communicable disease.26 More than 75% of the morbidity burden from mental disorders falls on low- and middle-income countries, who face the toughest dilemmas in prioritising and assigning healthcare resources. The great majority of individuals with mental disorders receive inadequate treatment or no treatment at all. The World Mental Health Survey found that, in developing countries, 35.5%–50.3% of individuals with severe mental disorders had received no treatment during the previous year, while in the developed world, this figure was 76.3%–85.4%.27 The existing disparity between those who need treatment and those who receive it varies from 32% to 78%, depending on the disorder.28

The public health implications of clinical usefulness have shaped the WHO approach to revising the ICD in several important respects. First, development of the ICD-11 must be an international endeavour. Ensuring the strong participation of developing countries is both a challenge and a requirement. Creating a system of diagnosis that, for these countries, is clinically useful and may be a means of reducing the disease burden is not simply a matter of modifying classifications previously elaborated by and for mental health specialists working in the developed world.

A second, closely related issue is that the revision process and the products it yields must be multilingual. Many specific cultural traits and national perspectives are embodied in language, and if there is no attention to translation and linguistic equivalence throughout the classification development process, reduced clinical usefulness is a predictable result for the non-English versions. WHO activities related specifically to development of the ICD-11 classifications for mental and behaviour disorders are being carried out in more than 20 languages. Field studies that have been completed thus far aiming to identify the general structure of the classification have been conducted entirely in 2 languages, simultaneously: English and Spanish.

Third, the revision must be a multidisciplinary endeavour. As mentioned above, the great majority of individuals around the world who have mental disorders will never see a psychiatrist. If the purpose is to make the ICD-11 classification for mental and behaviour disorders a tool that contributes to reducing the disease burden worldwide, it will have to be one that a wide range of healthcare professionals can use—in particular, the staff of primary care teams.

For the WHO-driven ICD-11 development process, taking all the above into consideration, clinical usefulness will be defined by the following factors:

  • its role as a means of communication (between clinicians and patients, family members, and healthcare administrators)

  • the features required for it to be implemented in clinical practice, such as the precision of its descriptions, its ease of use, and its feasibility in different healthcare settings

  • its usefulness in choosing interventions and its role in decision-making for clinical management

We also believe that consideration should be given to whether the proposed changes in diagnostic categories will contribute to improving clinical results in terms of both the individual and the population.

For the WHO, this classification revision project should lead to the development of a new instrument oriented more to the needs of daily clinical practice in different healthcare settings and should lay the foundation for an integrated model of mental health care in the future.

Conflicts of interest

The authors have no conflicts of interest to declare.

References
[1]
World Health Organization.
International classification of diseases and related health problems, 10th revision.
WHO, (1992),
[2]
American Psychiatric Association.
Diagnostic and statistical 234 manual of mental disorders.
American Psychiatric Association, (2000),
[3]
S.E. Hyman.
The diagnosis of mental disorders: the problem of reification.
Annual Review of Clinical Psychology, 6 (2010), pp. 155-179
[4]
H. Garb.
Clinical judgment and decision making.
Annual Review of Clinical Psychology, 1 (2005), pp. 167-195
[5]
Rethinking the DSM: a psychological perspective,
[6]
D.S. Charney, D.H. Barlow, K. Botteron, J.D. Cohen, D. Goldman, R.E. Gur, et al.
Neuroscience research agenda to guide development of a pathophysiologically based classification system.
A research agenda for DSM-V, pp. 31-83
[7]
N.C. Andreasen.
DSM and the death of phenomenology in America: an example of unintended consequences.
Schizophrenia Bulletin, 33 (2007), pp. 108-112
[8]
M.B. First.
Clinical utility in the revision of the diagnostic and statistical manual of mental disorders (DSM).
Professional Psychology: Research and Practice, 41 (2010), pp. 465-473
[9]
R. Kendall, A. Jablensky.
Distinguishing between the validity and utility of psychiatric diagnoses.
American Journal of Psychiatry, 160 (2003), pp. 4-12
[10]
R.C. Kessler, W.T. Chiu, O. Demler, E.E. Walters.
Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the national comorbidity survey replication.
Archives of General Psychiatry, 62 (2005), pp. 617-627
[11]
R.F. Krueger, Y.E. Chentsova-Dutton, K.E. Markon, D. Goldberg, J. Ormel.
A cross-cultural study of the structure of comorbidity among common psychopathological syndromes in the general health care setting.
Journal of Abnormal Psychology, 107 (2003), pp. 216-227
[12]
D.H. Barlow, L.B. Allen, M.L. Choate.
Toward a unified treatment for emotional disorders.
Behavior Therapy, 35 (2004), pp. 205-230
[13]
J.M. Gorman, J.M. Kent.
SSRIs and SNRIs: broad spectrum of efficacy beyond major depression.
Journal of Clinical Psychiatry, 60 (1999), pp. 33-39
[14]
C.A. Brinkley, J.P. Newman, T.A. Widiger, D.R. Lynam.
Two approaches to parsing the heterogeneity of psychopathy.
Clinical Psychology: Science and Practice, 11 (2004), pp. 69-94
[15]
G. Parker, K. Fletcher, M. Hyett, D. Hadzi-Pavlovic, M. Barrett, H. Synnott.
Measuring melancholia: the utility of a prototypic symptom approach.
Psychological Methods, 39 (2008), pp. 989-998
[16]
J.L. Tackett, R.F. Krueger, W.G. Iacono, M. McGue.
Symptom-based subfactors of DSM-defined conduct disorder: evidence for etiologic distinctions.
Journal of Abnormal Psychology, 114 (2005), pp. 483-487
[17]
D. Watson.
Subtypes, specifiers, epicycles, and eccentrics: toward a more parsimonious taxonomy of psychopathology.
Clinical Psychology: Science and Practice, 10 (2003), pp. 233-238
[18]
D. Watson, L.A. Clark.
Clinical diagnosis at the crossroads.
Clinical Psychology: Science and Practice, 13 (2006), pp. 210-215
[19]
R. Mays, A.V. Horwitz.
DSM-III and the revolution in the classification of mental illness.
Journal of the History of the Behavioral Sciences, 41 (2005), pp. 249-267
[20]
T. Insel, B. Cuthbert, M. Garvey, R. Heinssen, D.S. Pine, K. Quinn, et al.
Research domain criteria (RDoC): toward a new classification framework for research on mental disorders.
American Journal of Psychiatry, 167 (2010), pp. 748-751
[21]
G. Andrews, T. Anderson, T. Slade, M. Sunderland.
The classification of anxiety and depressive disorders: problems and solutions.
Depress Anxiety, 25 (2008), pp. 274-281
[22]
J. Krupinski, J.W.G. Tiller.
The identification and treatment of depression by general practitioners.
Australian and New Zealand Journal of Psychiatry, 35 (2001), pp. 827-832
[23]
A. Medow, S.J. Borowsky, S. Dysken, S.D. Hillson, S. Woods, T.J. Wilt.
Internal medical resident's ability to diagnose and characterise major depression.
Western Journal of Medicine, 17 (1999), pp. 35-40
[24]
P.S. Wang, S. Aguilar-Gaxiola, J. Alonso, M.C. Angermeyer, G. Borges, E.J. Bromet, et al.
Worldwide use of mental health services for anxiety, mood, and substance disorders: results from 17 countries in the WHO world mental health (WMH) surveys.
[25]
M. Zimmerman, I. Chelminski, J.B. McGlinchey, D. Young.
Diagnosing major depressive disorder: X. Can the utility of the DSM-IV symptom criteria be improved?.
Journal of Nervous and Mental Disorders, 194 (2006), pp. 893-897
[26]
World Health Organization.
The global burden of disease: 2004 update.
WHO, (2008),
[27]
World Health Organization World Mental Health Survey Consortium.
Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health surveys.
JAMA, 291 (2004), pp. 2581-2590
[28]
R. Kohn, S. Saxena, I. Levav, B. Saraceno.
Treatment gap in mental health care.
Bulletin of World Health Organization, 82 (2004), pp. 858-866

The opinions expressed in this editorial are those of the authors and do not necessarily represent the opinions of the World Health Organization.

Please cite this article as: Reed GM, Ayuso-Mateos JL. Hacia una clasificación Internacional de los Trastornos Mentales de la OMS de mayor utilidad clínica. Rev Psiquiatr Salud Ment (Barc.). 2011;4:113–6.

Copyright © 2011. SEP and SEPB
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.rpsmen.2021.02.003
No mostrar más